Eisai Inc. Enters Exclusive Agreement with Salix Pharmaceuticals, Ltd. to Co-promote “COLAZAL®” for the Treatment of Ulcerative Colitis in the U.S. Market

For Print September 5, 2007 Eisai Inc. (Headquarters: New Jersey, Chairman: Hajime Shimizu), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito), today announced the signing of a U.S. co-promotion agreement with Salix Pharmaceuticals, Ltd. (Headquarters: North Carolina, President and CEO: Carolyn Logan) in which Eisai receives exclusive rights to co-promote “ COLAZAL ®” (balsalazide disodium) Capsules 750 mg, and balsalazide disodium 1100 mg tablets, if and when approved by the U.S. Food and Drug Administration (FDA). “ COLAZAL ®” is a 5-aminosalicyclic acid (5-ASA) agent approved by FDA for the treatment of mildly to moderately active ulcerative colitis. Salix submitted a New Drug Application to the FDA in July, 2007 seeking approval to market a 1100 mg tablet formulation of balsalazide disodium for the treatment of mildly to moderately active ulcerative colitis. Along with successful marketing of its proton pump inhibitor “ AcipHex ®” (rabeprazole sodium), this co-promotion reinforces Eisai's presence in gastroenterology in the U.S. and further increases benefits to patients and their families. [Please see the following notes for the corporate profiles of Salix Pharmaceuticals] Contacts: Corporate Communications Department Eisai Co., Ltd. 81-3-3817-5120 < Notes to Editor > Corporate profiles of Salix Pharmaceuticals, Ltd. Headquarters: Raleigh, North Carolina, U.S.A. Incorporation: 1989 Number of employees: about 240 Corporate website: www.salix.com Full text

The release as fetched from its publisher. eisai.com ↗